The role of muscarinic receptors has been largely documented over the past few decades. Recently we demonstrated that the activation of M2 muscarinic receptors arrested cell proliferation and induced apoptosis in glioblastoma and in other tumour types. This paper aims to evaluate the expression of the M2 muscarinic receptor subtypes in different neuroblastoma cell lines and its role in the control of cell proliferation and survival. Neuroblastoma is the most common solid extracranial tumour, appearing during childhood and displaying a differentiated clinical behaviour. Considering the high homology between muscarinic receptor subtypes, we have identified Arecaidine Propargyl Ester (APE) as a selective orthosteric agonist for M2 muscarinic receptors. Using this agonist, we demonstrate how a selective activation of the M2 receptor subtype negatively modulates cell growth without affecting cell survival in different human neuroblastoma cell lines. As similarly demonstrated in other cell types, following the M2 receptor silencing by short-interference RNA, the effects of APE are completely abolished. We conclude by confirming the ability of APE to bind selectively M2 muscarinic receptor subtypes. Moreover, for the first time we demonstrate that M2 receptor activation inhibits cell growth also in human neuroblastoma cells, indicating that M2 receptors may be an interesting therapeutic target in several solid tumours.
Introduction
Muscarinic receptors belong to the G-proteins coupled receptors (GPCRs) family. Five muscarinic receptor subtypes were cloned in different mammalian and non-mammalian species [1] . Variance among subtypes is only limited to the carboxyl-and amino terminals of the proteins and to the third cytoplasmic loop [2] . The identification of selective ligands for muscarinic receptors has encountered difficulties due to the high degree of homology between subtypes and the frequent co-expression of more than one receptor in same tissue. Conversely, the lack of selective agonists has long limited their use in the treatment of different pathologies.
In fact, the roles of muscarinic receptors in different neurodegenerative and neurological diseases as well as in cancer is well known [3] [4] [5] [6] . The identification of muscarinic agonists has proved to be even more complex. Several studies in systems expressing either native or transfected receptor subtypes indicated that the effectiveness of an agonist is not only dependent on the subtype's selective binding affinity, but can be modified also by the availability of the specific receptor subtype [7] . Generally, when we consider molecules with agonist function, we think of several ligands able to interact with the orthosteric site of the receptor. In general, non-selective orthosteric agonists are more common, while it is more difficult to identify agonists able to bind selectively with only one muscarinic receptor subtype (Fig. 1) .
Selective binding of a single receptor subtype followed by its functional activation was used to design muscarinic agonists, and potentially in treating specific pathologies (Table 1 ). In the past, we identified a new M2 receptor subtype agonist named Arecaidine Propargyl Ester (APE). This molecule is a synthetic derivative from Arecoline, an alkaloid extracted by the areca nut, the fruit of the areca palm. Arecoline is a partial agonist of M 1 , M 2 , M 3 and M 4 muscarinic acetylcholine receptors. On the other hand, its synthetic derivate APE shows high selectivity for M2 subtype, as previously demonstrated by pharmacologically binding experiments [8, 9] . In our previous study, we demonstrated the ability of APE to inhibit cell proliferation and survival in different tumour types via M2 muscarinic receptors [10] [11] [12] . Neuroblastoma is the most common type of solid extracranial tumour, appearing during childhood. Among the solid childhood tumours, neuroblastoma is the second most widespread with an incidence of 10 cases per million each year. It originates from the neural crest cell, with prevalence in those cells that should form the sympathetic nervous system and adrenal medulla [13] . The most aggressive form of tumour shows amplification of N-myc, whose overexpression is usually associated with poor survival [14] . Considering the inability of all therapies available to efficiently arrest tumour progression, the identification of new drugs able to impair proliferation and cell survival appears relevant to design new therapeutic protocols. Premised on our previous studies, we have evaluated the ability of M2 orthosteric agonist APE to modulate cell proliferation and survival in human neuroblastoma cell lines and 
Materials and methods

Cell cultures
Human Neuroblastoma cell line SK-N-BE was cultured in RPMI 1640 (Roswell Park Memorial Institute, Sigma, St. Louis, MO, USA) supplemented with 10 % fetal bovine serum (FBS) (Immunological Sciences, Rome, Italy), 50 mg/ml streptomycin, 50 IU/ml penicillin, 2 mM glutamine (Sigma), and maintained at 37 °C, in atmosphere of 90 % of air and 5 % of CO 2 . Human Neuroblastoma cell line SK-N-SH was cultured in DMEM (Dulbecco's Modified Eagle's Medium, Sigma) supplemented with 10 % FBS, 50 mg/ml streptomycin, 50 IU/ml penicillin, 2 mM glutamine (Sigma), and, 1 % non-essential amino-acids (Sigma) and maintained at 37 °C, in atmosphere of 90 % of air and 10 % of CO 2 . Human Neuro-epithelioma cell line SK-N-MC was cultured in MEM (Minimum Essential Medium, Sigma) supplemented with 10 % FBS, 50 mg/ml streptomycin, 50 IU/ml penicillin, 2 mM glutamine (Sigma), and, 1 % non-essential amino-acids (Sigma) and maintained at 37 °C, in atmosphere of 90 % air and 10 % of CO 2 .
Cell viability assays
The cells were seeded on 24-well plate at the density of 2 × 10 4 cells/well. After 24 h cells were treated with cholinergic agonist Arecaidine propargyl ester hydrobromide (1-Methyl-1,2,5,6-tetrahydro-3-pyridine carboxylic acid propargyl ester hydrobromide; APE) (Sigma Aldrich, St. Louis, MO, USA) [11, 12] at dif- ferent time points (ranging from 24 to 72 h). Cell growth was assessed by colorimetric assay based on 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma-Aldrich, St. Louis, MO, USA) metabolization according to Mossman method [20] . For each well, the OD at 570 nm was measured by GloMax Multi Detection System (Promega, Madison, WI, USA). Cell viability was also determined by trypan blue staining. Trypan blue solution (Sigma-Aldrich, St. Louis, MO, USA) was added to cell suspension (1:10; v/v). After 5 min, the number of blue-stained (non-viable) and unstained cells (viable) was counted by Bürcker chamber. The data were calculated as the percentage of dead on total cells (see Table 2 ).
Western blot
Cells were lysed with Lysis buffer (Tris 10 mM, NP40 0.5 %, NaCl 150 mM) containing protease inhibitors (50×; Sigma 
RNA extraction and RT-PCR analysis
Total RNA was extracted using Total RNA extraction Mini kit (FMB, PA, USA) following the manufacturer' instructions, and then digested with DNAse I (Ambion-Life Technologies Italia, Monza, Italy). For each sample, 2 μg of total RNA was reverse transcribed for 60 min at 37 °C with Random Primers (Promega, Madison, WI, USA) and M-MLV reverse transcriptase (Promega, Madison, WI, USA). Primers and GoTaq Green Master Mix (Promega, Madison, WI, USA) were added to 100 ng of cDNA. The expression of all the five muscarinic receptors transcripts was evaluated by semi-quantitative RT-PCR analysis using the following primers:
Knockdown of M2 receptor
SK-N-BE cells were plated in 6-well plates at the density of 3 × 10 5 cells/well or in 24-well plate at the density of 5 × 10 3 cell/well for western blot analysis and MTT assay, respectively. After 24 h were transfected with a pool of siRNAs selective for human M2 receptor (CHRM2) as previously described [11, 12] . The transfection was carried out for 60 h with 60 nM M2-siRNA pool (Riboxx Life Sciences, Radebeul, Germany) using the transfection reagent HappyFect (Tecrea, London, UK) according to the manufacturer's instructions. Cells were harvested 60 h following transfection and western blot analysis was performed to determine the level of M2 receptor. For the analysis of cell growth by MTT assay, 100 mM APE was added for additional 48 h in fresh medium (except for the control) after transfection. Sequences of the M2-siRNA pool used were previously described [12] .
Statistical analysis
Student's t test and one-way ANOVA test followed by Bonferroni's post test were used to evaluate statistical significance within the different samples. Results were considered statistically significant at p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***).
Results and discussion
Expression of muscarinic receptors in neuroblastoma cell lines
We have investigated the effects of M2 muscarinic receptors in several neuroblastoma cell lines. The semiquantitative RT-PCR analysis showed that transcript for all five muscarinic receptors subtypes were expressed in SK-N-BE. Only the M4 transcript appeared absent or faintly expressed in SK-N-SH and SH-N-MC ( Fig. 2a) . Interestingly, M2 mRNA appeared expressed in all cell lines, although at a different level.
Western blot analysis revealed the expression of M2 receptor proteins in different neuroblastoma cell lines (Fig. 2b ). As results, the level of the expression of the M2 protein appeared inversely correlated with the mRNA levels. In fact where the M2 transcript level was apparently lower (SK-N-SH), the protein level results higher ( Fig. 2a and b ).
Analysis of cell growth and survival
Albeit several muscarinic receptor subtypes were expressed in neuroblastoma cell lines, the activation of all muscarinic receptors by no selective orthosteric agonist muscarine (100 μM) did not induce any modifications in neuroblastoma cell proliferation (see Supplementary Fig. 1 ). This effect is probably dependent on the simultaneous activation of all muscarinic receptor subtypes that activating several signal transduction pathways, may induce a balance between the second messengers downstream different muscarinic receptor subtype activation. On the contrary, previous research demonstrated how the M2 agonist APE is able to significantly inhibit cell growth in different tumour types (glioblastoma and urothelial bladder cancer cells) [10] [11] [12] . Considering the expression of the M2 subtype also in neuroblastoma cell lines, we investigated the ability of APE to modulate cell growth in three different of them. The MTT assay revealed the ability of APE to downregulate cell growth, although in unequal manners in the three cell lines (Fig. 3) . In particular, the low concentration of APE (3 and 12.5 μM) did not appear to affect neuroblastoma cell growth. In accordance with previous studies [10] [11] [12] , only 50 and 100 μM concentrations appeared to significantly inhibit cell growth. A 25 μM APE concentration inhibited cell growth at a lower level only in the SK-N-SH cell line. It is interesting to observe how the sensitivity of neuroblastoma cell line is directly correlated to the M2 protein levels. In fact, the cell line that resulted more responsive to M2 agonist was the SK-N-SH, which showed higher levels of the M2 receptor protein. Contrarily, the SK-N-MC cell line resulted more resistant to the treatment; apparently, 3, 12.5, 25, and 50 μM APE concentrations did not cause any significant reduction of cell growth, but only a mere slowdown. In order to explain whether a reduction in cell growth had been the result of decreased cell proliferation or survival, we have assessed the number of dead cells using the exclusion test by trypan blue staining. The micrographs reported in Fig. 4 showed that the cells treated with 100 μM APE, presented a decreased cell density compared with untreated cells (control condition). However, there were no cells clearly detached from the substrate thereby signalling absence of dead cells.
This observation was confirmed by the data obtained by trypan blue staining, which showed a percentage of dead cells in APE-treated samples not significantly different from the respective control in all experimental conditions and in all three cell lines (Table 2) . Seemingly, an increase in dead cells resulted after 48 h of APE treatment only in SK-N-MC. This result proves how APE has no toxic effect on neuroblastoma cells in general, as reported in the case of other tumours [15] . Altogether these evidence suggests that APE may negatively modulate cell proliferation in neuroblastoma and hence cause a slowdown of cell division at low doses (12.5, 25 μM), paired with an arrest of cell proliferation when used at high doses (50 and 100 μM). This notwithstanding, the three cell lines respond differently depending on APE concentration. This may depend upon levels of expression of the M2 receptors as well as the possibly different binding affinity for APE. In order to confirm that APE selectively binds only M2 receptor subtypes and to exclude that the high dose of APE may activate other muscarinic receptor subtypes, the SK-N-BE cells were transfected with a pool of siRNA, able to knock down the expression of human M2 muscarinic cholinergic receptors (CHRM2). In this instance, our western blot analysis demonstrated how after siRNA transfection (60 nM each/well) the expression of M2 receptors was significantly reduced (Fig. 5a ). MTT assay performed in un-transfected cells and in M2 siRNA transfected cells, in the absence or in the presence of 100 μM APE, showed that the decreased cell number observed with APE in un-transfected cells disappeared after siRNA transfection (Fig. 5b ).
Negative modulation of protoncogenes by M2 receptor activation
In order to explain the possible mechanism causing the decreased neuroblastoma cell proliferation after APE treatment, we investigate the ability of APE to modulate the expression of protoncogenes implicated in the neuroblastoma tumorigenesis. Upregulation or genomic amplification of oncogenes c-myc and N-myc are associated to high tumor malignancy and poor prognosis for the patients [16, 17] . Considering the role played by these oncogenes in neuroblastoma cell proliferation, we investigated the ability of APE to modulate the expression of c-myc and n-myc expression in all neuroblastoma cells lines considered in the present study. The analysis by RT-PCR analysis has clearly indicated the ability of M2 agonist APE to negatively modulate the expression of both oncogenes expression in SK-N-BE and SH-N-MC ( Fig. 6a, b) . SK-N-SH instead does not express N-myc as previously demonstrated [18] , but only c-myc. However the expression of c-myc appeared down-regulated after APE treatment also in SK-N-SH (Fig. 6c ).
Conclusions
The results obtained in this paper, following suit from our previous data [11, 12] confirm the APE as preferred M2 orthosteric muscarinic agonist. Considering that M2 receptors in general have inhibitory effects, we have dem- onstrated that its selective activation in neuroblastoma as well as in other tumour types (glioblastoma, breast cancer and urothelial bladder cancer cells) can cause a significant inhibition of tumour cell proliferation.
In particular in neuroblastoma, the anti-proliferative effects mediated by M2 receptor activation may be mediated by the downregulated expression of c-myc and N-myc oncogenes, largely involved in neuroblastoma cell proliferation and malignancy.
Altogether, these data confirm the M2 receptors as a new promising therapeutic target in cancer therapy. However, further research should aim at identifying a more selective agonist, able to produce similar effects but at a lower concentration in order to reduce potential side effects of high dosage of APE. Recently we have tested a new M2 dualsteric muscarinic agonist that may come out as an excellent therapeutic device for treatment of several solid tumours [7, 19] . 
